National Pingtung University of Science & Technology

Mei-Li Wu

Hso-Chi Chaung

Wen-Bin Chung

Guan-Ming Ke

Hui-Ju Hung

Ann Ying-An Chen

Tzou-Chi Huang

Ko-Tung Chang

The present invention relates to a recombinant antigen and an isolated polynucleotide of porcine reproductive and respiratory syndrome virus (PRRSV), a composition including the same and a method of making the same. The recombinant antigen is a chimeric protein of PRRSV dual structural proteins and T-cell epitope. The polynucleotide encodes an amino acid sequence of the recombinant antigen. The recombinant protein expressed by the polynucleotide in an eukaryotic expression system can be beneficial for mass production and purification. An immunogenic composition including the recombinant antigen can promote pro-inflammatory M1-phenotype polarization of porcine alveolar macrophages (PAMs), reduce receptor CD163 expression that is mediated for viral entry and activate T helper (Th1) immune responses, thereby being applied to a vaccine composition against PRRSV.

Recombinant antigen and method of making the same, isolated polynucleotide of porcine reproductive and respiratory syndrome virus (PRRSV) and immunogenic composition including the same

The present invention relates to an in vitro immune synapse system and a method of in vitro evaluating immune response using the same. The in vitro immune synapse system includes antigen-presenting cells (APCs) and at least one cell type of several specific T cell subtypes isolated from peripheral blood mononuclear cells (PBMCs), all of which is from a same individual of pigs. When a test sample is co-cultured in the in vitro immune synapse system for a given period, it can be determined that the test sample is immunogenic, immunostimulatory or not according to the immunization-related changes of these cells, thereby potentially replacing some kinds of animal experimentation.

In vitro immune synapse system and method of in vitro evaluating immune response using the same

The present invention relates to a nucleic acid-based adjuvant and a porcine vaccine composition including the same. The nucleic acid-based adjuvant, which is a nucleic acid fragment consisting of a sequence listing as SEQ ID NO: 1, can be used as the nucleic acid-based adjuvant of a vaccine composition, thereby elevating the protective ability of the porcine vaccine composition.

Nucleic acid-based adjuvant and porcine vaccine composition including the same

The present invention is directed to a recombinant fusion antigen gene, a recombinant fusion antigen protein and a subunit vaccine composition having the same against infection of porcine reproductive and respiratory syndrome virus (PRRSV). A recombinant fusion antigen gene, which encodes glycoprotein GP5 with truncated N'-terminal decoy epitope, a linker sequence and membrane protein M, followed by codon optimization, is expressed by a baculovirus expression system in vitro, thereby enhancing a yield of the recombinant fusion antigen protein. The recombinant fusion antigen protein can be applied in a subunit vaccine composition, for providing vaccinated animals with better protection ability without the risks of virulent spread and virulent recovery.

Recombinant fusion antigen gene, recombinant fusion antigen protein and subunit vaccine composition having the same against infection of porcine reproductive and respiratory syndrome virus

The present invention provides a method for detecting a beta-glucan having immunomodulatory activity in a human cell, which uses a test cell line that stably expresses human dectin-1 molecule on the cell surface and does not express other glucan receptors and a specific amount of a marker beta-glucan that specifically binds to human dectin-1 molecule for detection.

Growing community of inventors

Neipu, Taiwan

Mei-Li Wu